Introduction
============

Small noncoding RNAs complex with proteins to regulate key cellular functions.[@b1-bic-6-2014-037],[@b2-bic-6-2014-037] The potential of small noncoding RNAs to influence pathophysiological processes is best exemplified by miRNAs, which function in cell differentiation, cell signaling, tumorigenesis, and the pathogenesis of multiple diseases.[@b3-bic-6-2014-037],[@b4-bic-6-2014-037] Recently, noncoding RNAs with well-known functions, such as tRNA, rRNA, snoRNA, and YRNA, have been reported to generate smaller RNAs whose characteristics imply specific processing and function.[@b5-bic-6-2014-037],[@b6-bic-6-2014-037] A variety of stresses can induce the cleavage of tRNAs and YRNAs inside the cell to yield shorter noncoding RNA species.[@b7-bic-6-2014-037]--[@b9-bic-6-2014-037] We have reported that tRNA- and YRNA-derived small RNAs circulate in the blood as components of larger particles, and that circulating tRNA derivatives can be physiologically regulated.[@b10-bic-6-2014-037],[@b11-bic-6-2014-037] More recently, others have reported tRNA- and YRNA-derived small RNAs in another biological fluid, semen.[@b12-bic-6-2014-037] Their functions in biological fluids are not yet known, but precedent for such small RNAs carrying out signaling functions is provided by miRNAs that circulate in mammalian blood, enter target cells, modulate gene expression, and serve as markers of diseases.[@b13-bic-6-2014-037]--[@b16-bic-6-2014-037] In particular, tumor-derived miRNAs circulate in serum and plasma, and are emerging as novel blood-based markers for cancer detection and monitoring.[@b13-bic-6-2014-037],[@b17-bic-6-2014-037]--[@b20-bic-6-2014-037]

tRNA-derived molecules termed 5′ tRNA halves result from cleavage of full-length tRNAs by the ribonuclease angiogenin in response to stress.[@b21-bic-6-2014-037],[@b22-bic-6-2014-037] They interact with components of the translation initiation complex, promote assembly of stress granules carrying stalled preinitiation complexes, and inhibit mRNA translation.[@b22-bic-6-2014-037]--[@b25-bic-6-2014-037] YRNA-derived fragments remain largely unexplored. Full-length YRNAs are components of the autoantigenic Ro ribonucleoproteins, play a role in chromosomal DNA replication and quality control of non-coding RNA,[@b26-bic-6-2014-037]--[@b28-bic-6-2014-037] and are overexpressed in various cancers.[@b29-bic-6-2014-037] YRNA-derived fragments were first observed in cells exposed to apoptotic stimuli,[@b30-bic-6-2014-037] or poly(I:C).[@b9-bic-6-2014-037] YRNA fragments were also detected in non-stressed cells,[@b9-bic-6-2014-037] and in vesicles released by immune cells.[@b31-bic-6-2014-037]

Our group and others have recently reported the presence of YRNA fragments and 5′ tRNA halves in serum.[@b10-bic-6-2014-037],[@b11-bic-6-2014-037],[@b32-bic-6-2014-037] The tRNA- and YRNA-derived molecules are not contained in exosomes or microvesicles, but circulate as particles of 100--300 kDa, indicating they may be actively secreted through an RNA-binding protein-dependent pathway. YRNA fragments are dramatically more abundant in human than in mouse serum,[@b10-bic-6-2014-037] possibly reflecting the much greater copy number of YRNA genes and pseudogenes in humans.[@b29-bic-6-2014-037] While the cells that produce circulating YRNA fragments are not yet known, circulating 5′ tRNA halves may originate from blood cells and hematopoietic tissues, where they are detected at significant levels.[@b11-bic-6-2014-037] The functions of circulating tRNA and YRNA derivatives are not yet known; however, we found that serum levels of specific subtypes of 5′ tRNA halves change markedly with age, and that these changes can be prevented by calorie restriction.[@b11-bic-6-2014-037]

Our recent observation that tRNA- and YRNA-derived fragments circulate in the serum and the evidence that circulating tumor-derived miRNAs may participate in signaling prompted us to explore the possibility that serum levels of 5′ tRNA halves or YRNA fragments may change in response to cancer. We used small RNA sequencing to assess the abundance of 5′ tRNA halves and YRNA fragments circulating in the sera of a small group of women with breast cancer, as well as normal controls; the results prompted us to study datasets obtained from a larger group of breast cancer cases. Our findings suggest that breast cancer may be associated with significant alterations in the serum levels of fragments derived from specific tRNAs and YRNAs.

Results and Discussion
======================

Characterization of small RNAs circulating in serum of normal subjects and breast cancer patients
-------------------------------------------------------------------------------------------------

We used breast cancer to explore the possibility that changes in circulating 5′ tRNA halves and 5′ YRNA fragments, besides circulating miRNAs, can be associated with a disease state. We deep sequenced serum small RNAs and compared levels of the various types of circulating small RNAs in five breast cancer and five control subjects. The breast cancer subjects were a diverse group, and some samples were obtained after treatment ([Table 1](#t1-bic-6-2014-037){ref-type="table"}). Sequencing reads from each serum sample were aligned to the human genome. The size distribution of aligned reads revealed three peaks, at 20--24 nt, 25--29 nt, and 30--33 nt, in both normal and cancer groups ([Fig. 1A and B](#f1-bic-6-2014-037){ref-type="fig"}). The peak pattern is similar to the pattern we recently reported in the human and mouse sera.[@b10-bic-6-2014-037],[@b11-bic-6-2014-037]

Sequencing reads from both normal and cancer samples were pooled to inspect the length distribution of reads, the pattern and size of peaks, and the types and proportions of small RNAs from which the reads are derived from. Pooling is used only to examine the general characteristics of the reads, and not to measure the differential expression of small RNAs between control and cancer groups. A combined total of 122,490,155 pre-processed reads were aligned to the hg19 human genome to generate a dataset of 110,652,186 mapped reads (90.34%), ranging in size from 18 to 49 nt. Annotation and length distribution analyses revealed that reads in the 20--24 nt and 25--29 nt peaks were derived from miRNAs and YRNAs, respectively, while the 30--33 nt peak consists of reads mapping to both YRNA and tRNA genes ([Fig. 1C](#f1-bic-6-2014-037){ref-type="fig"}). Further annotation analysis showed that of the total 110,652,186 reads mapping to the human genome, 98,999,062 (89.5%) map to known small RNAs, of which 41% were annotated as miRNAs, 38% as YRNAs, 21% as tRNAs, and \<1% as rRNA, snRNA, and snoRNA ([Fig. 1D](#f1-bic-6-2014-037){ref-type="fig"}). The significant presence in serum of tRNA- and YRNA-derivatives in addition to miRNA is consistent with our previous findings.[@b10-bic-6-2014-037],[@b11-bic-6-2014-037]

These datasets also produced evidence of a novel type of circulating YRNA fragments. We recently reported that in human serum, \>95% of YRNA-aligned reads map to the 5′ ends of YRNA genes and \>99% of tRNA-aligned reads map to the 5′ ends of tRNA genes.[@b10-bic-6-2014-037],[@b11-bic-6-2014-037] In the present study, we took a closer look at the YRNA-derived reads that align to the 3′ ends of YRNA genes. In this dataset, among the total pooled reads that map to YRNA genes, 5.3% and 94.7% of YRNA reads align to the 3′ and 5′ ends of YRNA genes, respectively ([Fig. 2A](#f2-bic-6-2014-037){ref-type="fig"}). Since YRNA-derived reads are found in both the 25--29 nt and the 30--33 nt peaks ([Fig. 1C](#f1-bic-6-2014-037){ref-type="fig"}), we calculated the proportions of the reads mapping to the 3′ end versus the 5′ end of YRNA genes in the 25--29 nt and the 30--33 nt peaks. Almost all of the reads in the 30--33 nt peak align to the 5′ ends of YRNAs ([Fig. 2B](#f2-bic-6-2014-037){ref-type="fig"}). In contrast, only 13.0% of the reads in the 25--29 nt peak align to the 5′ end of YRNAs, while 87% align to the 3′ end ([Fig. 2B](#f2-bic-6-2014-037){ref-type="fig"}). This means that the circulating 5′ YRNA fragments are of two sizes, 25--29 nt and 30--33 nt, while the circulating 3′ YRNA fragments are of only one size, 25--29 nt. This is supported by Northern blot analysis of RNA extracted from serum ([Fig. 2C](#f2-bic-6-2014-037){ref-type="fig"}). A probe derived from the 5′ end of the RNY4 gene ([Fig. 2C](#f2-bic-6-2014-037){ref-type="fig"}, left panel) detected a major band at the 30-nt marker (consistent with the 30--33 nt peak), and a minor band below the 30-nt marker (consistent with the 25--29 nt peak). An oligonucleotide probe complementary to the 3′ end of the RNY4 gene detected only a minor band below the 30-nt marker, consistent with the 25--29 nt peak ([Fig. 2C](#f2-bic-6-2014-037){ref-type="fig"}, right panel). These results indicate the presence in human serum of a major population of 30--33 nt YRNA fragments mostly derived from the 5′ end of YRNAs, and a minor population of 25--29 nt YRNA fragments almost exclusively derived from the 3′ end of YRNAs. The biogenesis and biological significance of these two types of circulating YRNA fragments remain to be elucidated.

Altered abundance of specific circulating 5′ tRNA halves and YRNA fragments in breast cancer patients
-----------------------------------------------------------------------------------------------------

### 5′ tRNA halves

We compared serum abundance of 5′ tRNA halves in datasets from individual breast cancer and normal subjects using the Bioconductor package edgeR.[@b33-bic-6-2014-037] There are 625 tRNA genes, each of them potentially capable of producing 5′ tRNA halves. Our analysis suggests that a breast cancer diagnosis is associated with alterations---either increase or decrease---in the circulating levels of 5′ tRNA halves derived from specific tRNA isoacceptors ([Table 2](#t2-bic-6-2014-037){ref-type="table"}). The individuals with breast cancer had significantly increased circulating levels of 5′ tRNA halves derived from the isoacceptors of tRNA-Arg, -Asn, -Cys, -Gln, -Gly, -Leu, -Ser, -Trp, and -Val, and decreased circulating levels of 5′ tRNA halves derived from tRNA-Asp, and -Lys.

### YRNA fragments

We analyzed serum levels of YRNA fragments with the Bioconductor package edgeR[@b33-bic-6-2014-037] as for the 5′ tRNA halves. Here also a breast cancer diagnosis is associated with alterations---either increase or decrease---in levels of circulating YRNA fragments ([Table 3](#t3-bic-6-2014-037){ref-type="table"}). Among the 20 types of increased YRNA fragments, 19 were derived from the 3′ end, while only one was derived from the 5′ end of YRNA genes. All five YRNA fragments that decreased in abundance were derived from the 5′ ends of YRNA genes. In this study, and in a previous one,[@b10-bic-6-2014-037] we found that serum 5′ YRNA fragments are much more abundant than 3′ YRNA fragments (a ratio of \~20 to 1) ([Fig. 2A](#f2-bic-6-2014-037){ref-type="fig"}). However, despite the preponderance of the 5′ YRNA fragments, many more 3′ than 5′ YRNA fragments displayed altered serum levels associated with breast cancer. 3′ end YRNA fragments are 25--29 nt, while 5′ end YRNA fragments can be 25--29 nt or 30--33 nt ([Fig. 2B](#f2-bic-6-2014-037){ref-type="fig"}). Thus, there may be a specific association between breast cancer and the minor 25--29 nt population of circulating 3′ YRNA fragments. The functional significance of this specificity in size and YRNA end is not clear, especially since there is little known about the biological role of YRNA fragments.

Thus, we find that the abundance of specific circulating 5′ tRNA halves and 3′ and 5′ YRNA fragments is different when normal individuals are compared with a group of breast cancer patients. This might imply that these processed circulating small RNAs are somehow involved in the disease process. However, the breast cancer group is small, and the characteristics of the individual cases are fairly disparate in terms of stage and treatment status, making it difficult to draw any strong conclusions from this information. For this reason, we examined circulating small RNAs in a larger group of breast cancer cases.

Breast cancer clinical characteristics are associated with changes in abundance of 5′ tRNA halves and YRNA fragments
--------------------------------------------------------------------------------------------------------------------

The findings described above suggest that breast cancer may, either directly or indirectly, exert multifarious effects on levels of circulating small RNAs. While these changes could potentially serve as biomarkers of disease, they might also provide clues to the pathophysiology of systemic effects during cancer progression. To further explore this finding, we made use of existing datasets of serum small RNAs from a group of 42 individuals diagnosed with breast cancer (Gene Expression Omnibus \[GEO\] Series GSE49035). These specimens were obtained prior to treatment, with information on tumor stage, ER, PR, and HER2 expression, and presence of inflammation. Cases in which relapse subsequently occurred were recorded. The datasets have previously been analyzed with regard to miRNA expression;[@b34-bic-6-2014-037] we used them to search for associations between characteristics of the tumors and levels of specific 5′ tRNA halves and YRNA fragments.

We analyzed the 42 datasets with the same methods described for the pilot dataset above. We first pooled the datasets and assessed the composition of the various circulating small RNAs in the group as a whole. As in the pilot dataset ([Fig. 1D](#f1-bic-6-2014-037){ref-type="fig"}) and in our previous study,[@b10-bic-6-2014-037] we find that the great bulk of reads are derived from miRNAs (45%), tRNAs (41%), and YRNAs (13%), with negligible fractions of other types ([Fig. 1E](#f1-bic-6-2014-037){ref-type="fig"}). We then asked if, within this group of breast cancer cases, clinical characteristics were associated with changes in circulating 5′ tRNA halves or YRNA fragments.

### 5′ tRNA halves

We found that tumor characteristics were associated with changes in circulating 5′ tRNA halves ([Fig. 3](#f3-bic-6-2014-037){ref-type="fig"} and Supplementary [Table 1](#t1-bic-6-2014-037){ref-type="table"}). ER+ tumor cases showed a decline in abundance of 26 specific circulating tRNA halves in comparison to ER− tumors. Similarly, PR+ and HER2+ status was associated with declines in 41 and 8 specific 5′ tRNA halves, respectively. Inflammatory breast cancer, on the other hand, was associated with increases in five specific 5′ tRNA halves, while eventual relapse was associated with increased levels of 18 specific 5′ tRNA halves at the time of diagnosis. Tumor stage was not associated with significant differences in serum levels of any 5′ tRNA halves.

### YRNA fragments

We carried out the same comparative analysis for circulating YRNA fragments ([Fig. 4](#f4-bic-6-2014-037){ref-type="fig"} and Supplementary [Table 2](#t2-bic-6-2014-037){ref-type="table"}). Again, tumor characteristics, with the exception of inflammation, were associated with differences in serum levels of some YRNA fragments. The direction of change was consistent in the ER+ and PR+ groups (down) and in the relapse group (up), although not in the HER2+ group. The ER+, PR+, and HER2+ tumor cases were associated with a decrease in abundance of 15, 4, and 13 specific circulating YRNA fragments, respectively. The HER2+ status was also associated with an increase in abundance of three specific circulating YRNA fragments. Relapse was associated with decreased level of only one but the increased levels of 31 circulating YRNA fragments. Tumor stage was associated with decreased level of one and the increased levels of two circulating YRNA fragments.

### Inter-individual differences

We asked if the highly significant differences between groups assorted by clinical characteristics were a feature of the groups as a whole, or were caused by a subset of individuals within a group. When levels of the 5′ tRNA halves in individual cases were inspected, we noted that the significant change in expression within a group was driven by a large difference in a few individuals ([Fig. 5](#f5-bic-6-2014-037){ref-type="fig"}). Comparison of the 5′ tRNA half expression levels in the ER+ and ER− groups, and in the relapse and nonrelapse groups, shows that there is significant inter-individual variation. Nevertheless, when abundance of 5′ tRNA halves changed in association with a clinicopathologic characteristic, the direction of the change was consistent among cases within a group. The most striking finding came from comparison of the relapse and nonrelapse groups. Two of the 10 individuals in the relapse group account for most of the difference between these two groups ([Fig. 5](#f5-bic-6-2014-037){ref-type="fig"}). Levels of 5′ tRNA halves were very high in these two individuals, while levels in the other eight in the relapse group were uniformly low, as were levels in the 31 cases in the nonrelapse group. Both of these two individuals were ER−, PR−, HER2−, Stage 3 without inflammation. This pattern is highly significant; we speculate that this high expression in these individuals is in some way connected to their later relapse.

Similar patterns of inter-individual differences were observed in the levels of circulating YRNA fragments; the differences between groups assorted by clinical characteristics were caused by a subset of individuals within a group.

In summary, we find that serum abundance of both 5′ tRNA halves and YRNA fragments differs between groups of breast cancer cases sorted by tumor characteristics, and these differences seem to be accounted for by a subset of individuals within a group. Do these differences (between normal individuals and breast cancer patients, and between patients whose tumors have different characteristics) have any biological or clinical significance? It cannot be concluded from this data that the level of any specific 5′ tRNA half or YRNA fragment has strong predictive value. However, we speculate that the association between breast cancer and changes in these novel circulating RNA species reflects some aspect of either the biology of the tumor or the reaction of the individual to a tumor.

The significant association between breast cancer characteristics and alterations in serum levels of 5′ tRNA halves raises the possibility of a causal connection between some aspect of the disease process and the 5′ tRNA halves. A more definite conclusion is impeded by the rudimentary state of knowledge regarding the function of 5′ tRNA halves. Currently, the only described function of 5′ tRNA halves is inhibition of translation in cultured cells subjected to a variety of stressors.[@b21-bic-6-2014-037]--[@b25-bic-6-2014-037],[@b35-bic-6-2014-037] Stress-induced tRNA fragments promote assembly of stress granules, and inhibit mRNA translation.[@b23-bic-6-2014-037],[@b25-bic-6-2014-037] It is not known if specific subtypes of 5′ tRNA halves have different activities in this mechanism. Whether they originate from the cancer itself, or from cells affected by the cancer, it is tempting to speculate that 5′ tRNA halves may mediate systemic effects of cancer. We currently have no information on the abundance of 5′ tRNA halves in breast cancer cells. We have shown that in mice, under normal physiological conditions, 5′ tRNA halves are concentrated in hematopoietic and lymphoid tissues, and present in other tissues at very low levels that may reflect residual blood cells.[@b11-bic-6-2014-037] Although the origin and destinations of the serum particles carrying 5′ tRNA halves are not yet known, the abundance of 5′ tRNA halves in blood cells suggests that they may produce the serum particles. This raises interesting questions in regard to the current findings. Does breast cancer itself change the serum composition of 5′ tRNA halves, or is the change caused by some physiological response to the disease?

Finally, the physiological role of serum 5′ tRNA halves is as yet unknown, but there is clearly potential for them to be taken up by peripheral tissues where they may alter biological processes;[@b23-bic-6-2014-037] thus our finding might suggest a marker of physiologic changes accompanying malignancy. Further insights into this issue will be promoted by a better understanding of the origins and destinations of serum 5′ tRNA halves, and more extensive information regarding their relationship with cancer syndromes.

The findings with YRNA fragments are similar to those with 5′ tRNA halves: differences in the serum abundance of specific subtypes, related to breast cancer diagnosis or breast tumor characteristics. The finding implies that a type- and end-specific biogenesis and/or release of the circulating YRNA fragments is affected by cancer through some mechanism, possibly even direct secretion of fragments by cancer cells. Full-length YRNAs are overexpressed in some solid tumors.[@b29-bic-6-2014-037] 3′ end fragments derived from human RNY5 were detected in MCF7 mammary adenocarcinoma cells.[@b9-bic-6-2014-037] Moreover, 3′ end fragments of human RNY5 were significantly induced upon treatment of cancerous and noncancerous cell lines with the stressor poly(I:C), a double-stranded RNA mimic that is an immunostimulant.[@b9-bic-6-2014-037] Human YRNA-derived fragments of size range 22--25 nt and 27--36 nt were also shown to be induced in cells exposed to apoptotic stimuli, where the induced YRNA fragments remain bound to Ro after they are cleaved in a caspase-dependent manner.[@b30-bic-6-2014-037]

Conclusions
===========

We have found that, in some individuals diagnosed with breast cancer but not yet treated, specific circulating tRNA halves and YRNA fragments show altered abundance in comparison to the group as a whole. Changes in serum levels of specific 5′ tRNA halves occur in some individuals with ER− tumors, and in individuals who later relapsed. Because the numbers of cases were relatively small, and we have little information on variation in circulating tRNA halves and YRNA fragments in normal individuals, these results do not establish a clear relationship between the disease and the changes. However, we note that changes in specific 5′ tRNA halves always occurred in the same direction, and occurred only in individuals with certain clinical characteristics, consistent with a relationship between disease characteristics and the levels of specific 5′ tRNA halves. A better understanding of this relationship will require a larger number of cases with normal controls.

Materials and Methods
=====================

Blood collection and serum preparation
--------------------------------------

The study was approved by the University of California at Riverside Institutional Review Board and performed in accordance with the Helsinki Declaration II and Standards of Good Clinical Practice. Blood samples were collected from five healthy adult women between 30 and 57 years of age and five women with breast cancer between 47 and 58 years of age after obtaining informed consent. Blood was collected in BD Vacutainer SST tubes (\#367985, BD), incubated for 15 minutes at room temperature to allow coagulation, and centrifuged at 5,000 g for 10 minutes. The serum supernatant was transferred to new tubes, centrifuged at 16,000 g for 15 minutes to remove any residual cells and debris, and stored at −80°C.

RNA isolation and small RNA library construction
------------------------------------------------

Total RNA, including small RNA, was isolated with Qiagen miRNeasy kit (\#217004) according to the manufacturer's protocol with the following alterations: 2 mL of Qiazol reagent was mixed with 0.4 mL serum and the aqueous phase was loaded onto a single column from the MinElute Cleanup Kit (\#74204, Qiagen). RNA was eluted in 20 μL of RNase-free water. One-fourth (5 μL) of the RNA isolated from each serum sample was used to construct sequencing libraries with the Illumina TruSeq Small RNA Sample Prep Kit (\#RS-200-0012, Illumina), following the manufacturer's protocol. Libraries' quality was validated by checking the size, purity, and concentration of the amplicons on the Agilent Bioanalyzer High Sensitivity DNA chip (\#5067-4626, Genomics Agilent). Equimolar amounts of libraries were pooled and sequenced on an Illumina HiSeq 2000 instrument to generate 50 base reads.

Bioinformatics analysis of sequencing reads
-------------------------------------------

FASTX-Toolkit ([hannonlab.cshl.edu](http://hannonlab.cshl.edu)) was used to trim the adaptor sequences, and discard low-quality reads. The filtered reads were mapped to the human (hg19) genome with Bowtie version 0.12.8[@b36-bic-6-2014-037] using the "end-to-end k-difference (−v)" alignment mode and allowing up to two mismatches. In addition, this mode of alignment was combined with options (−k 1--- best) that instructed Bowtie to report only the best alignment if more than one valid alignment exists. BEDTools[@b37-bic-6-2014-037] was used to annotate the mapped sequencing reads using noncoding RNAs from Ensembl GRCh37 release 70, miRNAs from miRBase 20 ([mirbase.org](http://mirbase.org)), and tRNAs from Genomic tRNA Database.[@b38-bic-6-2014-037]

The Bowtie alignment files were also analyzed with BEDTools to count the reads that align to tRNA genes in the Genomic tRNA Database and YRNA genes and pseudogenes in the noncoding RNAs of Ensembl GRCh37 release 70. The tRNA and YRNA read counts were further analyzed with the Bioconductor package edgeR[@b33-bic-6-2014-037] to measure changes in the levels of circulating tRNA halves and YRNA fragments in the experimental groups.

Northern blot analysis
----------------------

RNA for Northern blot analysis was extracted from 0.2 mL serum. The extracted RNA was separated on 15% denaturing polyacrylamide gels, transferred, and fixed to a membrane by chemical cross-linking.[@b39-bic-6-2014-037] Hybridization of the membranes was carried out overnight at 42°C in ULTRAhyb-Oligo Buffer (Invitrogen) with[@b32-bic-6-2014-037] P-5′-end-labeled oligonucleotide probes against the 5′ end (5′-AGTTCTGATAACCCACTACCATCGGACCAGCC) or 3′ end (5′-AGCCAGTCAAATTTAGCAGTGGGGGGTTGTAT) of RNY4. Following hybridization and washing, the blots were exposed to X-ray films for detection of signals.

Analysis of breast cancer data from the GEO public repository
-------------------------------------------------------------

Raw serum small RNA sequencing data in the GEO Series GSE49035[@b34-bic-6-2014-037] was downloaded, preprocessed, mapped to the human (hg19) genome with Bowtie, and annotated with BEDTools according to the parameters used to analyze the pilot samples above. The tRNA and YRNA read counts were analyzed with the Bioconductor package edgeR to assess the associations between changes in the levels of circulating tRNA halves and YRNA fragments and the characteristics of the tumors (stage, ER, PR, and HER2 expression, presence of inflammation, and subsequent relapse). The algorithm of edgeR fits a negative binomial model to the count data, estimates dispersion, and measures differences using the generalized linear model likelihood ratio test, which is well suited for the analysis of experiments with multiple factors, such as the simultaneous analysis of the characteristics of the tumors (stage, ER, PR, and HER2 expression, presence of inflammation, and subsequent relapse) performed here. The fitted count data was analyzed by performing pairwise comparisons between the two possible alternatives of each clinical characteristic: stage (2 versus 3), ER (positive versus negative), PR (positive versus negative), HER2 (positive versus negative), presence of inflammation (yes versus no), and subsequent relapse (yes versus no). EdgeR uses the Benjamini and Hochberg method to adjust *P*-values to control the false discovery rate. The level of statistical significance for the difference between two possible alternatives of each clinical characteristic was set for an adjusted *P*-value \<0.05.

Supplementary Data
==================

###### 

**Supplementary table 1.** Fold changes in serum abundance of specific 5′ tRNA halves associated with breast cancer clinicopathologic characteristics.

**Supplementary table 2.** Fold changes in serum abundance of specific YRNA fragments associated with breast cancer clinicopathologic characteristics.
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![**Length distribution and annotation of reads from serum small RNAs of five healthy females and five females diagnosed with breast cancer.** Length of mapped reads from five normal (**A**) and five cancer samples (**B**) is plotted against read abundance. Colors of the bars denote the individual sources of the serum small RNAs (normal and breast cancer samples). (**C**) Length distribution of pooled sequencing reads from all 10 samples plotted against abundance of reads according to their annotation. Length distribution is plotted against abundance of the reads annotated as miRNAs, YRNAs, tRNAs, rRNAs, or other sRNAs (snRNAs and snoRNAs). (**D**) Pie chart showing the percent of reads (pooled from both normal and breast cancer) mapping to the indicated specific types of small RNAs. (**E**) Pie chart showing the percent of reads mapping to the indicated types of small RNAs in pooled datasets obtained by sequencing of small RNAs in the sera of 42 newly diagnosed breast cancer cases.](bic-6-2014-037f1){#f1-bic-6-2014-037}

![**Characteristics of sequencing reads that map to YRNA genes.** (**A**) Pooled reads from all 10 samples were used to compare the number of reads that align with 5′ or 3′ ends of YRNA genes. The *y*-axis represents the percentage of the total YRNA reads that map to YRNA genes. (**B**) Percentage of reads mapping to 5′ and 3′ ends of YRNAs in the 25--29 nt peak (black) and the 30--33 nt peak (gray). Almost 100% of the reads in the 30--33 nt peak align to the 5′ end of YRNAs, while a significant majority of reads in the 25--29 nt peak align to the 3′ end of YRNAs. (**C**) Northern blot analysis of RNA extracted from 0.2 mL of human serum. The blot was hybridized to ^32^P-end-labeled oligonucleotide probes complementary to the 5′ end (left panel) or 3′ end (right panel) of RNY4. Arrows indicate the positions of the major (30--33 nt) and minor (25--29 nt) bands. M: Decade markers.](bic-6-2014-037f2){#f2-bic-6-2014-037}

![**Changes in serum abundance of specific 5′ tRNA halves in breast cancer cases sorted by clinicopathologic characteristics.** Shown in the graph are all 5′ tRNA halves found to have significant differences in abundance when 42 newly diagnosed breast cancer cases were compared for clinicopathologic characteristics. The *y*-axis denotes fold change in abundance of a 5′ tRNA half when groups are compared. Eventual relapse is associated with increased serum levels of a small set of 5′ tRNA halves, while ER expression is associated with decreased serum levels of a broader group of 5′ tRNA halves. Inflammatory disease is associated with increased serum levels of a separate group of 5′ tRNA halves. Tumor stage is not shown because no significant differences were found between Stage 2 and Stage 3 cases. An adjusted *P*-value \<0.05 was set as the level of statistical significance for the difference between two possible alternatives of each clinical characteristic (stage \[2 versus 3\], ER \[positive versus negative\], PR \[positive versus negative\], HER2 \[positive versus negative\], presence of inflammation \[yes versus no\], and subsequent relapse \[yes versus no\]).](bic-6-2014-037f3){#f3-bic-6-2014-037}

![**Changes in serum abundance of specific YRNA fragments in breast cancer cases sorted by clinicopathologic characteristics.** Shown in the graph are all YRNA fragments found to have significant differences in abundance when 42 newly diagnosed breast cancer cases were compared for clinicopathologic characteristics. The *y*-axis denotes fold change in the indicated YRNA fragments. Eventual relapse was associated with increased serum levels of a broad group of YRNA fragments, while ER expression was associated with decreased serum levels of an overlapping group. Inflammatory status is not shown because no significant differences were found. An adjusted *P*-value \<0.05 was set as the level of statistical significance for the difference between two possible alternatives of each clinical characteristic (stage \[2 versus 3\], ER \[positive versus negative\], PR \[positive versus negative\], HER2 \[positive versus negative\], presence of inflammation \[yes versus no\], and subsequent relapse \[yes versus no\]).](bic-6-2014-037f4){#f4-bic-6-2014-037}

![**Inter-individual variation in expression of 5**′ **tRNA halves.** Expression levels of the indicated 5′ tRNA halves are represented as counts per million reads (cpm) in each individual breast cancer case. For each group, the mean (dotted line) and the standard error of the mean (error bars) are indicated. Comparisons were carried out between ER− and ER+ groups (**A**), and relapsed and nonrelapsed groups (**B**). Each tRNA isoacceptor is identified by its genomic position in the human hg19 genome. In (**B**), the two individuals showing increased levels of different 5′ tRNA halves are the same in each graph.](bic-6-2014-037f5){#f5-bic-6-2014-037}

###### 

Clinical characteristics of breast tumors.

  PATIENT     CHARACTERISTICS
  ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient 1   63 years old; infiltrating ductal carcinoma, grade 2, ER+, PR+.
  Patient 2   47 years old; infiltrating ductal carcinoma, grade 2, ER+, PR+.
  Patient 3   47 years old; Infiltrating ductal carcinoma with lymph node metastasis, ER+, PR+.
  Patient 4   58 years old; breast carcinoma treated with surgery and chemotherapy with subsequent widespread osseous metastases.
  Patient 5   55 years old; right mastectomy with pathology revealing a pathologic stage IIIA (ypT3ypN2\@4 out of 6\@M0) invasive carcinoma and received radiation therapy and adjuvant letrozole.

###### 

Breast cancer-associated changes in the serum levels of 5′ tRNA halves.

  TRNA[1](#tfn1-bic-6-2014-037){ref-type="table-fn"}   GENOMIC COORDINATES        NORMAL (cpm)[2](#tfn2-bic-6-2014-037){ref-type="table-fn"}   TUMOR (cpm)[2](#tfn2-bic-6-2014-037){ref-type="table-fn"}   FC[3](#tfn3-bic-6-2014-037){ref-type="table-fn"}   *P*-VALUE
  ---------------------------------------------------- -------------------------- ------------------------------------------------------------ ----------------------------------------------------------- -------------------------------------------------- -----------
  Arg-CCG                                              chr17:66016013-66016085    49                                                           145                                                         3.0                                                0.003
  Arg-CCT                                              chr7:139025446-139025518   23                                                           47                                                          2.1                                                0.006
  Arg-TCT                                              chr1:159111401-159111474   6                                                            17                                                          2.7                                                0.005
  chr1:94313129-94313213                               1714                       4033                                                         2.4                                                         0.004                                              
  chr9:131102355-131102445                             6                          13                                                           2.3                                                         0.007                                              
  chr17:8024243-8024330                                12                         22                                                           1.9                                                         0.018                                              
  Asn-GTT                                              chr1:148248115-148248188   26                                                           72                                                          2.8                                                0.008
  Cys-GCA                                              chr4:124430005-124430076   85                                                           164                                                         1.9                                                0.008
  chr17:37023898-37023969                              553                        1073                                                         1.9                                                         0.010                                              
  chr17:37025545-37025616                              87                         181                                                          2.1                                                         0.003                                              
  chr17:37309987-37310058                              83                         163                                                          2.0                                                         0.007                                              
  chr17:37310744-37310815                              80                         163                                                          2.0                                                         0.006                                              
  Gln-TTG                                              chr6:145503859-145503930   3                                                            7                                                           2.1                                                0.036
  Gly-TCC                                              chr1:161432166-161432237   2                                                            5                                                           2.5                                                0.016
  Leu-AAG                                              chr5:180528840-180528921   5                                                            12                                                          2.2                                                0.007
  chr14:21078291-21078372                              2                          5                                                            2.4                                                         0.023                                              
  Ser-GCT                                              chr6:26305718-26305801     33                                                           55                                                          1.7                                                0.032
  chr6:27265775-27265856                               3                          7                                                            2.3                                                         0.019                                              
  Trp-CCA                                              chr6:26331672-26331743     23                                                           39                                                          1.7                                                0.041
  Val-AAC                                              chr3:169490018-169490090   15896                                                        30605                                                       1.9                                                0.017
  chr5:180591154-180591226                             16231                      31153                                                        1.9                                                         0.017                                              
  chr5:180596610-180596682                             16125                      31093                                                        1.9                                                         0.016                                              
  chr5:180615416-180615488                             3021                       5485                                                         1.8                                                         0.021                                              
  chr5:180645270-180645342                             4304                       8291                                                         1.9                                                         0.016                                              
  chr6:27618707-27618779                               4259                       8194                                                         1.9                                                         0.017                                              
  chr6:27648885-27648957                               4344                       8315                                                         1.9                                                         0.017                                              
  chr6:27721179-27721251                               4232                       8154                                                         1.9                                                         0.017                                              
  Val-CAC                                              chr1:149298555-149298627   4331                                                         8279                                                        1.9                                                0.017
  chr1:149684088-149684161                             4391                       8347                                                         1.9                                                         0.018                                              
  chr1:161369490-161369562                             4414                       8422                                                         1.9                                                         0.015                                              
  chr5:180524070-180524142                             16273                      31118                                                        1.9                                                         0.017                                              
  chr5:180529253-180529325                             4466                       8487                                                         1.9                                                         0.018                                              
  chr5:180600650-180600722                             16731                      31644                                                        1.9                                                         0.018                                              
  chr5:180649395-180649467                             4395                       8333                                                         1.9                                                         0.017                                              
  chr6:26538282-26538354                               16594                      31522                                                        1.9                                                         0.018                                              
  chr6:27173867-27173939                               272                        516                                                          1.9                                                         0.020                                              
  chr6:27248049-27248121                               8352                       17964                                                        2.2                                                         0.018                                              
  chr6:27696327-27696399                               25                         45                                                           1.8                                                         0.044                                              
  Val-TAC                                              chr6:27258405-27258477     200                                                          354                                                         1.8                                                0.035
  Asp-GTC                                              chr6:27471523-27471594     94                                                           56                                                          −1.7                                               0.039
  chr12:125411891-125411962                            29                         15                                                           −1.9                                                        0.020                                              
  chr12:125424193-125424264                            31                         16                                                           −1.9                                                        0.015                                              
  chr17:8125556-8125627                                30                         14                                                           −2.2                                                        0.009                                              
  Lys-TTT                                              chr6:27559593-27559665     115                                                          61                                                          −1.9                                               0.016
  chr6:28918806-28918878                               4322                       2407                                                         −1.8                                                        0.042                                              

**Notes:**

tRNA isoacceptor identity with corresponding genomic positions in the human hg19 genome.

Average tRNA read count for the indicated experimental group reported as counts per million (cpm) reads in the sequenced library.

Fold change calculated by EdgeR from comparison between the normal and breast cancer serum samples.

###### 

Breast cancer-associated changes in the serum levels of YRNA-derived fragments.

  YRNA[1](#tfn4-bic-6-2014-037){ref-type="table-fn"}   GENOMIC COORDINATES         NORMAL (cpm)[2](#tfn5-bic-6-2014-037){ref-type="table-fn"}   TUMOR (cpm)[2](#tfn5-bic-6-2014-037){ref-type="table-fn"}   FC[3](#tfn6-bic-6-2014-037){ref-type="table-fn"}   *P*-VALUE   END[4](#tfn7-bic-6-2014-037){ref-type="table-fn"}
  ---------------------------------------------------- --------------------------- ------------------------------------------------------------ ----------------------------------------------------------- -------------------------------------------------- ----------- ---------------------------------------------------
  Y_RNA.400                                            chr8:98784541-98784653      7.4                                                          4.1                                                         −1.8                                               0.014       5′
  Y_RNA.353                                            chr1:155092966-155093074    7.8                                                          4.6                                                         −1.7                                               0.041       5′
  Y_RNA.31                                             chrX:135653864-135653974    103.4                                                        63.8                                                        −1.6                                               0.024       5′
  Y_RNA.112                                            chr3:164840501-164840611    108.4                                                        71.2                                                        −1.5                                               0.039       5′
  Y_RNA.639                                            chr14:56535161-56535245     9.9                                                          6.5                                                         −1.5                                               0.035       5′
  Y_RNA.367                                            chrX:19394892-19394993      4.5                                                          8.3                                                         1.8                                                0.014       5′
  Y_RNA.166                                            chr20:16651286-16651387     10.4                                                         18.4                                                        1.8                                                0.014       3′
  Y_RNA.597                                            chr2:206890317-206890421    20.2                                                         35.6                                                        1.8                                                0.029       3′
  Y_RNA.535                                            chr12:42848522-42848623     25.0                                                         43.3                                                        1.7                                                0.013       3′
  Y_RNA.180                                            chr15:59867827-59867922     10.8                                                         18.2                                                        1.7                                                0.044       3′
  Y_RNA.168                                            chr14:100049354-100049455   28.3                                                         47.3                                                        1.7                                                0.007       3′
  Y_RNA.450                                            chr6:34789222-34789319      14.9                                                         24.5                                                        1.6                                                0.017       3′
  Y_RNA.212                                            chr11:107955640-107955741   24.5                                                         40.1                                                        1.6                                                0.024       3′
  Y_RNA.511                                            chr11:64063509-64063610     21.8                                                         35.3                                                        1.6                                                0.022       3′
  Y_RNA.481                                            chr15:30965953-30966046     20.4                                                         33.0                                                        1.6                                                0.021       3′
  Y_RNA.505                                            chr15:52454948-52455049     21.2                                                         34.0                                                        1.6                                                0.040       3′
  Y_RNA.148                                            chr6:106902703-106902804    26.8                                                         43.0                                                        1.6                                                0.032       3′
  Y_RNA.469                                            chr20:431307-431406         14.1                                                         22.6                                                        1.6                                                0.037       3′
  Y_RNA.170                                            chr4:158689165-158689265    10.0                                                         15.6                                                        1.6                                                0.031       3′
  Y_RNA.595                                            chr2:113337061-113337161    5.7                                                          8.9                                                         1.6                                                0.040       3′
  RNY4P18                                              chr9:113859605-113859693    206.0                                                        328.7                                                       1.6                                                0.037       3′
  RNY4P25                                              chr1:151411476-151411571    507.1                                                        777.0                                                       1.5                                                0.039       3′
  Y_RNA.218                                            chr17:43148810-43148911     16.8                                                         25.6                                                        1.5                                                0.035       3′
  Y_RNA.699                                            chrX:41175741-41175842      5.7                                                          8.6                                                         1.5                                                0.017       3′
  Y_RNA.492                                            chr12:123252646-123252747   15                                                           23                                                          1.5                                                0.017       3′

**Notes:**

YRNA identity with corresponding genomic positions in the human hg19 genome.

Average YRNA read count for the indicated experimental group reported as counts per million (cpm) reads in the sequenced library.

Fold change calculated by EdgeR from comparison between the normal and breast cancer serum samples.

Indicates whether the sequencing reads map to the 5′ or 3′ end of YRNAs.
